Summary Comments
- Most frequently detected viruses in March 2024 (all age groups):
- Rhino/Enterovirus: 32.6%
- Rhinovirus: 25.3%
- RSV: 21%
- Epidemiological Week 1–13:
- SARS-CoV-2 positivity remained stable during the last 5 weeks.
- Influenza A & B remained low:
- Influenza A: 3.7%
- Influenza B: 1.7% (week 13)
- RSV increased to 27.8% positivity in week 13.
Respiratory Viral Multiplex PCR and SARS-CoV-2 PCR: All Age Groups
February 2024:
- Rhino/Enterovirus: 36.6%
- Rhinovirus: 32.6%
- RSV: 7.9%
- SARS-CoV-2: 6.9%
- Parainfluenza 1-4: 5.4%
- Adenovirus: 4.7%
- Influenza A: 3.7%
- Influenza B: 1.0%
March 2024:
- Rhino/Enterovirus: 32.6%
- Rhinovirus: 25.3%
- RSV: 21%
- SARS-CoV-2: 5.26%
- Parainfluenza 1-4: 7.7%
- Adenovirus: 9.2%
- Influenza A: 3.7%
- Influenza B: 3.3%
SARS-CoV-2, Influenza A & B, and RSV – Week-by-Week Positivity (Weeks 1–13):
- SARS-CoV-2: ~Stable
- Influenza A: Peaked at 3.7% (week 13)
- Influenza B: Peaked at 1.7% (week 13)
- RSV: Rose to 27.8% in week 13
Atypical Bacterial Pathogens (Weeks 1–13)
Weekly Case Totals:
- Bordetella pertussis: 5, 9, 7, 6, 9, 9, 5, 6, 4, 4, 1, 3, 1
- Mycoplasma pneumoniae: 5, 15, 13, 23, 10, 11, 15, 20, 14, 13, 17, 14, 6
- Chlamydia pneumoniae: 5, 7, 10, 8, 18, 12, 15, 22, 7, 15, 18, 30, 17
Legionella pneumophila:
- 1 case detected during March 2024
Age Distribution:
B. pertussis:
- 0–6 months: 19%
- 6–12 months: 9%
- 1–5 years: 29%
- 6–12 years: 17%
- 13–18 years: 2%
- 19–64 years: 17%
65 years: 7%
M. pneumoniae:
- 0–6 months: 2%
- 6–12 months: 8%
- 1–5 years: 26%
- 6–12 years: 27%
- 13–18 years: 7%
- 19–64 years: 25%
65 years: 5%
C. pneumoniae:
- 0–6 months: 2%
- 6–12 months: 2%
- 1–5 years: 50%
- 6–12 years: 30%
- 13–18 years: 3%
- 19–64 years: 12%
65 years: 1%
Paediatric Respiratory Viral Multiplex PCR Data (Ages 0–12)
<1 Year Age Group
February 2024:
- Rhino/Enterovirus: 42.2%
- Rhinovirus: 34.3%
- RSV: 18.3%
- Parainfluenza 1-4: 11.9%
- Adenovirus: 6.6%
- SARS-CoV-2: 6.6%
- Influenza A: 5.7%
- Influenza B: 1.3%
March 2024:
- RSV: 39.1%
- Rhino/Enterovirus: 39.9%
- Rhinovirus: 30.1%
- Parainfluenza 1-4: 13.4%
- Adenovirus: 9.0%
- SARS-CoV-2: 5.0%
- Influenza A: 5.7%
- Influenza B: 0.8%
1–5 Year Age Group
February 2024:
- Rhino/Enterovirus: 55.5%
- Rhinovirus: 47.8%
- RSV: 14.4%
- Parainfluenza 1-4: 17.9%
- Adenovirus: 13.3%
- SARS-CoV-2: 11.2%
- Influenza A: 6.7%
- Influenza B: 1.7%
March 2024:
- RSV: 33.2%
- Rhino/Enterovirus: 48.4%
- Rhinovirus: 35.2%
- Parainfluenza 1-4: 21.4%
- Adenovirus: 16.9%
- SARS-CoV-2: 14.3%
- Influenza A: 6.1%
- Influenza B: 0.6%
6–12 Year Age Group
February 2024:
- Rhino/Enterovirus: 43.6%
- Rhinovirus: 40.1%
- Influenza B: 10.7%
- RSV: 2.5%
- SARS-CoV-2: 7.6%
- Parainfluenza 1-4: 5.5%
- Adenovirus: 5.2%
- Influenza A: 4.2%
March 2024:
- Rhino/Enterovirus: 32.5%
- Rhinovirus: 26.9%
- Influenza B: 10.7%
- RSV: 7.4%
- SARS-CoV-2: 1.6%
- Parainfluenza 1-4: 3.9%
- Adenovirus: 9.1%
- Influenza A: 2.8%
Continue Reading